Publications associées à History of cancer chemotherapy

Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth

Freddy Radtke, Nadine Fournier, Amber Dawn Bowler, Etienne Meylan, Anita Bodac, Justine Pascual, Vincent Roh

Elevated peripheral blood and tumor-infiltrating neutrophils are often associated with a poor patient prognosis. However, therapeutic strategies to target these cells are difficult to implement due to the life-threatening risk of neutropenia. In a genetica ...

Springernature2024

Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma

Paul Joseph Dyson, Valentin Simeonov, Fabien Kuttler, Irina Sinenko, Patrik Aouad

Retinoblastoma is the most common pediatric eye cancer. It is currently treated with a limited number of drugs, adapted from other pediatric cancer treatments. Drug toxicity and relapse of the disease warrant new therapeutic strategies for these young pati ...

WILEY2023

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation

Andrea Ablasser

Solid cancers exhibit a dynamic balance between cell death and proliferation ensuring continuous tumour maintenance and growth(1,2). Increasing evidence links enhanced cancer cell apoptosis to paracrine activation of cells in the tumour microenvironment in ...

NATURE PORTFOLIO2022

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Matthias Lütolf, Michele De Palma, Mario Leonardo Squadrito, Mauro Delorenzi, Sina Nassiri, Alan Nicolas Thierry Guichard, Nikolche Gjorevski, Simone Ragusa, Borja Prat Luri, Laureline Wetterwald

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential respon ...

2020

Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates

Paul Joseph Dyson, Rosario Scopelliti, Felix Daniel Bobbink, Patrycja Nowak-Sliwinska, Anna Katherine Renfrew

Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the dev ...

WILEY-V C H VERLAG GMBH2019

Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow

Michele De Palma

Macrophages modulate tumor response to chemotherapy; in this issue, Lossos and colleagues show that high-dose alkylating agents instigate a synthetic lethal program in lymphoma cells that is independent of DNA damage and involves recruitment and priming of ...

AMER ASSOC CANCER RESEARCH2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Mauro Delorenzi, Thibaut François Hugo Richard, Yu-Ting Huang

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due ...

Springer2019

Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration

Gianrocco Lazzari, Agata Mlynska

The management of advanced ovarian cancer is challenging due to the high frequency of recurrence, often associated with the development of resistance to platinum-based chemotherapy. Molecular analyses revealed the complexity of ovarian cancer with particul ...

SPANDIDOS PUBL LTD2019

A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1

Paul Joseph Dyson, Laure Menin, Wee Han Ang

Cisplatin [cis-diamminedichloroplatinum(II) (cis-DDP)] is one of the most successful anticancer agents effective against a wide range of solid tumors. However, its use is restricted by side effects and/or by intrinsic or acquired drug resistance. Here, we ...

National Academy of Sciences2019